DJE - Europa PA (EUR) Header Image
ISIN:
LU0159548683
As at:
16/01/2020
Bid:
359.01 EUR
Offer:
376.96 EUR

Monthly Commentary

With few exceptions the international stock markets gained in December. A key factor was the "Phase One" trade agreement which the USA and China agreed on and which is to be signed in mid-January. It essentially means that the USA will waive the introduction of various announced import duties and that China will import more agricultural goods from the USA. In Europe market participants also reacted positively to the Conservative victory in the British general election. In Germany the ifo business climate index improved again but various German and European economic indicators continued to disappoint. In this market environment the DJE - Europe index rose 2.13% in December. Its benchmark index MSCI Europe Net Total Return rose 2.13%. The fund benefited in particular from its investment into the overweight sectors real estate and construction & materials. In addition the energy and industrial sector - both sectors underweight in the fund - also made positive contributions to the fund's performance. Particularly pleasing individual stock results were achieved by, among others, the German copper producer Aurubis, the French biopharmaceutical company Genfit, the German software and online services company TeamViewer and the German real estate company Godewind. Nevertheless negative contributions to the fund came mainly from the non-cyclical consumer goods segment and the telecommunication and utility sector. Viewing individual stocks the British healthcare services company NMC Health, the French automotive supplier Valeo and the Munich-based payment services company Wirecard were particularly disappointing. During the month the fund management slightly expanded the sectors household goods and financial institutions. On the other hand, the fund moderately reduced its weighting in the industrial sector. Regionally British positions were expanded and French stocks were reduced in return. Because of these adjustments the fund's equity weighting rose slightly from 99.37% previous month to 99.62%. The cash ratio fell from 0.63% to 0.38%.

Legal Information / Disclaimer:

Figures subject to revision by the auditors on the reporting dates. The published information does not constitute investment advice or a recommendation, but only provides a brief summary of the key features of the fund. The current sales documents (Key Investor Information Document, prospectus, annual report and – if the annual report is older than eight months – the semi-annual report) for the respective investment funds form the sole basis for the purchase of securities. The sales documents are available at no charge at the respective fund company, the distribution company or at www.dje.de. All data and estimates are indicative and may change at any time. This information is based on our assessment of current legal and tax regulations. The data were carefully compiled, but no guarantee can be given for the accuracy of such information. All data are subject to change. The performance is calculated using the BVI (Bundesverband Investment und Asset Management e.V.) method, i.e. without taking into account the subscription fee. Individual expenses such as fees, commissions and other charges are not taken into account in the data and would have a detrimental effect on the performance if they were. The subscription fees payable reduce the invested capital as well as the performance depicted. Data on past performance are not a reliable indicator of future performance. The tax treatment depends on the individual circumstances of the investor and may be subject to change. Please see the prospectus for more detailed tax information. In connection with brokering fund units, the Dr. Jens Ehrhardt Group and its distribution partners may receive reimbursements from costs charged to the funds by the investment companies in accordance with the respective prospectuses. The units of this fund that are issued may only be sold or offered for sale in jurisdictions in which such offer or sale is permitted. Therefore the units of this fund may not be offered for sale or sold in the USA, or offered for sale or sold to or for the account of US citizens or US persons resident in the USA. This document and the information it contains may not be distributed in the USA. The distribution and publication of this document and the offer or sale of units may also be subject to restrictions in other jurisdictions.

*) © 2016 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.